Interestingly, the combination of CEA-TCB and an anti-PD-L1 blocking antibody led to increased frequency of intra-tumor CD4 and CD8 T-cells displaying a cytotoxic effector and effector memory phenotype; at the same time, the combination treatment lowered the frequency of putatively exhausted T-cells (characterized by co-expression of PD-1+Tim3+Lag3+ CD8 T-cells) and increased the frequency of T-cells having migratory capacity (characterized by CXCR3+ expression on CD8+ T-cells). The gene discussed is HAVCR2; the disease is neoplasm.